The Health-Related Quality of Life Impact of the COVID-19 Pandemic on People Living with Multiple Sclerosis and the General Population: A Comparative Study Utilizing the EQ-5D-5L with Psychosocial Bolt-Ons
- PMID: 39740771
- PMCID: PMC11688049
- DOI: 10.1002/brb3.70210
The Health-Related Quality of Life Impact of the COVID-19 Pandemic on People Living with Multiple Sclerosis and the General Population: A Comparative Study Utilizing the EQ-5D-5L with Psychosocial Bolt-Ons
Abstract
Objectives: Studies have shown that people living with multiple sclerosis (PwMS) were substantially impacted by the COVID-19 pandemic. However, no study has compared the overall health-related quality of life impact of the COVID-19 pandemic on PwMS and the general population. Differences would have implications for crises/pandemic management policies. This study aimed to compare the prevalence and health-related quality of life impact of COVID-19-related adversity (such as deteriorations in mental or physical health) in PwMS and the general population.
Methods: Cross-sectional data were obtained from the How Is Your Life Australian general population study (comprising subsamples with and without chronic disease) and the Australian MS Longitudinal Study from August to October 2020. Health-related quality of life was measured using health state utilities (HSUs; represented on a 0 [death] to 1 [full health] scale) generated by the EQ-5D-5L-Psychosocial. COVID-19-related adversity was measured via specialized survey items. Descriptive and multivariable regression analyses were conducted.
Results: A total of 1020 general population individuals and 1635 MS participants entered the study (mean age 52.4 and 58.4; female 52.4% and 80.2%, respectively). COVID-19-related adversity prevalence was higher among PwMS compared to the general population with and without chronic diseases (PR: 1.430 [CI: 1.153, 1.774] and PR: 1.90 [CI: 1.56, 2.32], respectively). However, the HSU impact of COVID-19-related adversity was not dependent on disease status (p > 0.20, test for interaction).
Conclusion: This study found that PwMS were more likely to experience COVID-19-related adversity compared to the general population, though the health-related quality-of-life impact was similar. This demonstrates that PwMS require additional support during national and global crises.
Keywords: COVID‐19; health state utility; multiple sclerosis; outcome measurement; quality of life.
© 2024 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
The quality of life impact of the COVID-19 pandemic and lockdowns for people living with multiple sclerosis (MS): evidence from the Australian MS Longitudinal Study.Qual Life Res. 2024 Jun;33(6):1675-1689. doi: 10.1007/s11136-024-03620-4. Epub 2024 Apr 5. Qual Life Res. 2024. PMID: 38578380 Free PMC article.
-
Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia.Qual Life Res. 2023 Feb;32(2):553-568. doi: 10.1007/s11136-022-03214-y. Epub 2022 Aug 29. Qual Life Res. 2023. PMID: 36036311 Free PMC article.
-
Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand.Eur J Health Econ. 2023 Aug;24(6):939-950. doi: 10.1007/s10198-022-01518-x. Epub 2022 Sep 23. Eur J Health Econ. 2023. PMID: 36149605 Free PMC article.
-
The psychological impact of Covid-19 pandemic on people with Multiple Sclerosis: A meta-analysis.Mult Scler Relat Disord. 2022 May;61:103774. doi: 10.1016/j.msard.2022.103774. Epub 2022 Mar 25. Mult Scler Relat Disord. 2022. PMID: 35381533 Free PMC article. Review.
-
A review of the psychometric properties of generic utility measures in multiple sclerosis.Pharmacoeconomics. 2014 Aug;32(8):759-73. doi: 10.1007/s40273-014-0167-5. Pharmacoeconomics. 2014. PMID: 24846760 Review.
References
-
- World Health Organization . 2015. International Statistical Classification of Diseases and Related Health Problems. 10th revision, 5th ed. Geneva, Switzerland: World Health Organization.
-
- Ahmad, H. , Campbell J., van der Mei I., Taylor B., and Palmer A.. 2018. Health Economic Impact of Multiple Sclerosis in Australia in 2017: An Analysis of MS Research Australia's Platform—The Australian MS Longitudinal Study (AMSLS). North Sydney, Australia: Multiple Sclerosis Australia. https://www.msaustralia.org.au/wp‐content/uploads/2018/08/health‐economi....
-
- Campbell, J. , van der Mei I., Taylor B., and Palmer A.. 2023. Health Economic Impact of MS in 2021: An Interim Update of Prevalence, Costs and Costs of Illness From 2017 to 2021. North Sydney, Australia: Multiple Sclerosis Australia. https://www.msaustralia.org.au/wp‐content/uploads/2023/02/health‐economi....
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials